Astra

UK-Swedish drugmaker AstraZeneca has established a clinical trial collaboration with Peregrine Pharmaceuticals to assess the safety and efficacy of bavituximab in combination with durvalumab (MEDI4736) in multiple solid tumours.

The Phase I / Ib trial has been designed to assess the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS) signalling pathway inhibitor bavituximab in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor durvalumab.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Bavituximab and durvalumab are investigational immunotherapies with different mechanisms, which will help the body’s immune system to fight against cancer.

Bavituximab is said to target and modulate the activity of phosphatidylserine, while durvalumab is a monoclonal antibody directed against programmed cell death ligand 1 (PD-L1).

AstraZeneca global medicines development, immuno-oncology head Robert Iannone said: "We believe that combination therapy in immuno-oncology has the potential to be a novel and highly effective approach to treating cancer."

See Also:

"We believe that combination therapy in immuno-oncology has the potential to be a novel and highly effective approach to treating cancer."

Both firms will partner on a non-exclusive basis to assess the combination of bavituximab and durvalumab with chemotherapy as a potential treatment in various solid tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study’s Phase I part is expected to establish a recommended dose regimen for the combination, while the Phase Ib part of the trial will evaluate safety and efficacy of the investigational combination.

Peregrine will take responsibility of the initial trial.

Peregrine president and CEO Steven King said: "Data generated to date have shown significant potential for combining bavituximab with agents targeting the PD-1 / PDL-1 pathway and we’re excited to further explore this approach in studies with durvalumab."

Image: AstraZeneca’s R&D Site in Mölndal, Sweden. Photo: courtesy of Erik031.